New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
Personalized medicine in lung cancer: what we need to know
TSK Mok - Nature reviews Clinical oncology, 2011 - nature.com
Lung cancer is a complex and often fatal disease. The recent discovery of activating
mutations in EGFR and fusion genes involving ALK has set the stage for personalized …
mutations in EGFR and fusion genes involving ALK has set the stage for personalized …
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
LV Sequist, BA Waltman, D Dias-Santagata… - Science translational …, 2011 - science.org
Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
Background: The epidermal growth factor receptor (EGFR) mutation T790M is reported in
approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a …
approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a …
Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling
Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib …
Purpose: Treatment of patients with oncogene-addicted cancers with tyrosine kinase
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
K Taniguchi, J Uchida, K Nishino, T Kumagai… - Clinical cancer …, 2011 - AACR
Purpose: Examination of somatic epidermal growth factor receptor (EGFR) mutations is now
a diagnostic routine for treatment of cancer using EGFR tyrosine kinase inhibitors (EGFR …
a diagnostic routine for treatment of cancer using EGFR tyrosine kinase inhibitors (EGFR …
Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European journal of …, 2011 - Elsevier
BACKGROUND: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
[HTML][HTML] Mechanisms of acquired resistance to tyrosine kinase inhibitors
Y Chen, L Fu - Acta Pharmaceutica Sinica B, 2011 - Elsevier
In recent years, structural and functional studies reveal that tyrosine kinases (TKs) act as the
essential components of signal transduction pathways that regulate cancer cell proliferation …
essential components of signal transduction pathways that regulate cancer cell proliferation …
Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
GR Oxnard, YY Janjigian, ME Arcila, CS Sima… - Clinical Cancer …, 2011 - AACR
Purpose: Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in
advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy …
advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy …